@article{CardaniSardiLaFerlaetal.2014,
  author    = {Cardani, Diego and Sardi, Claudia and La Ferla, Barbara and D'Orazio, Guiseppe and Sommariva, Michele and Marcucci, Fabrizio and Olivero, Daniela and Tagliabue, Elda and Koepsell, Hermann and Nicotra, Francesco and Balsari, Andrea and Rumio, Christiano},
  title     = {Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis},
  series = {Molecular Cancer},
  volume    = {13},
  journal   = {Molecular Cancer},
  number    = {23},
  issn      = {1476-4598},
  doi       = {10.1186/1476-4598-13-23},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-117352},
  year      = {2014},
  abstract  = {Background: Recent studies demonstrated that engagement of sodium glucose transporter 1 (SGLT-1) by orally administered D-glucose protects the intestinal mucosa from lipopolysaccharide (LPS)-induced injury. We tested whether SGLT-1 engagement might protect the intestinal mucosa from doxorubicin (DXR)- and 5-fluorouracil (5-FU)-induced injury in animal models mimicking acute or chronic mucositis. Methods: Mice were treated intraperitoneally with DXR, alone or in combination with 5-FU, and orally with BLF501, a glucose-derived synthetic compound with high affinity for SGLT-1. Intestinal mucosal epithelium integrity was assessed by histological analysis, cellular proliferation assays, real-time PCR gene expression assays and Western blot assays. Student's t-test (paired two-tailed) and X-2 analyses were used for comparisons between groups. Differences were considered significant at p < 0.05. Results: BLF501 administration in mice treated with DXR and/or 5-FU decreased the injuries to the mucosa in terms of epithelial integrity and cellular proliferative ability. Co-treatment with BLF501 led to a normal expression and distribution of both zonula occludens-1 (ZO-1) and beta-catenin, which were underexpressed after treatment with either chemotherapeutic agent alone. BLF501 administration also restored normal expression of caspase-3 and ezrin/radixin/moesin (ERM), which were overexpressed after treatment with DXR and 5-FU. In SGLT1-/- mice, BLF501 had no detectable effects. BLF501 administration in wild-type mice with growing A431 tumors did not modify antitumor activity of DXR. Conclusions: BLF501-induced protection of the intestinal mucosa is a promising novel therapeutic approach to reducing the severity of chemotherapy-induced mucositis.},
  language  = {en}
}
@article{GrebinykPrylutskaGrebinyketal.2019,
  author    = {Grebinyk, Anna and Prylutska, Svitlana and Grebinyk, Sergii and Prylutskyy, Yuriy and Ritter, Uwe and Matyshevska, Olga and Dandekar, Thomas and Frohme, Marcus},
  title     = {Complexation with C\(_{60}\) fullerene increases doxorubicin efficiency against leukemic cells in vitro},
  series = {Nanoscale Research Letters},
  volume    = {14},
  journal   = {Nanoscale Research Letters},
  number    = {61},
  doi       = {10.1186/s11671-019-2894-1},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-228257},
  year      = {2019},
  abstract  = {Conventional anticancer chemotherapy is limited because of severe side effects as well as a quickly evolving multidrug resistance of the tumor cells. To address this problem, we have explored a C\(_{60}\) fullerene-based nanosized system as a carrier for anticancer drugs for an optimized drug delivery to leukemic cells.Here, we studied the physicochemical properties and anticancer activity of C\(_{60}\) fullerene noncovalent complexes with the commonly used anticancer drug doxorubicin. C\(_{60}\)-Doxorubicin complexes in a ratio 1:1 and 2:1 were characterized with UV/Vis spectrometry, dynamic light scattering, and high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The obtained analytical data indicated that the 140-nm complexes were stable and could be used for biological applications. In leukemic cell lines (CCRF-CEM, Jurkat, THP1 and Molt-16), the nanocomplexes revealed 3.5 higher cytotoxic potential in comparison with the free drug in a range of nanomolar concentrations. Also, the intracellular drug's level evidenced C\(_{60}\) fullerene considerable nanocarrier function.The results of this study indicated that C\(_{60}\) fullerene-based delivery nanocomplexes had a potential value for optimization of doxorubicin efficiency against leukemic cells.},
  language  = {en}
}